Objective:To explore the clinical efficacy and safety of Duloxeline combined with Olanzapine in treatment of soma-tization disorder. Methods:A total of 100 patients with somatization disorder were randomly divided into study group and control group. The patients in study group were treated with duloxeline combined with olanzapine for 8 weeks, whereas those in control group were treated with duloxeline alone for 8 weeks. The clinical efficacy and side effects were assessed before and 2, 4, 6, and 8 weeks after the treatment by using Hamilton depression rating scale (HAMD-17), Hamilton anxiety scale (HAMA) and treatment emergent symptom scale (TESS). Results: For both study group and control group, the scores of HAMD-17 and HAMA after the treatment were signifi-cantly lower than those before the treatment (P<0. 01). The effective rate of study group was 81. 63% , while that of control group was 61. 7% , and the difference between the two groups tested by x2 was statistically significant (P<0. 05). 2 weeks after the treatment, the HAMD-17 score and HAMA score for study group decreased significantly than those for control group (P<0. 05). There was no statistical difference between the two groups in incidence rate of the adverse reactions (P>0. 05); however, the incidence rates of in-somnia, anorexia, and anxiety of study group were significantly lower than those of control group (all P<0. 05). Conclusions: For the treatment of somatization disorder, duloxeline combined with olanzapine works better and faster than duloxeline alone. It can improve the somatization symptoms like insomnia, anxiety, appetite and the like.%目的：探讨度洛西汀联合奥氮平治疗躯体化障碍临床疗效及安全性。方法：将100例躯体化障碍患者随机分为研究组与对照组，研究组患者以度洛西汀联合奥氮平治疗，对照组患者单用度洛西汀治疗，疗程8周。于患者治疗前及治疗后2、4、6、8周采用汉密尔顿抑郁量表(HAMD-17)、汉密尔顿焦虑量表(HAMA)和副反应量表(TESS)分别评定患者的临床疗效和不良反应。结果：治疗后两组患者 HAMD-17和 HAMA 评分均较治疗前显著减少(P<0.01)；研究组患者有效率为81.63%，对照组患者有效率为61.70%，两组患者有效率经 x2检验差异有统计学意义(P<0.05)；治疗2周末研究组患者 HAMD-17及 HAMA 评分均较对照组下降显著(P<0.05)。两组患者不良反应发生率差异无统计学意义(P>0.05)，但研究组患者在失眠、食欲减退、焦虑不安方面发生率明显低于对照组(P 均<0.05)。结论：度洛西汀联合奥氮平治疗躯体化障碍起效快、疗效优于单用度洛西汀；且能改善失眠、焦虑及食欲减退等躯体化症状。
展开▼
